Loading...
XSHG600535
Market cap3.02bUSD
Dec 27, Last price  
14.76CNY
1D
1.86%
1Q
-1.60%
Jan 2017
-50.20%
Name

Tasly Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:600535 chart
P/E
20.59
P/S
2.54
EPS
0.72
Div Yield, %
2.24%
Shrs. gr., 5y
-0.28%
Rev. gr., 5y
-13.57%
Revenues
8.67b
+0.94%
1,301,841,2531,465,866,9252,414,345,4042,794,905,7793,434,215,5273,992,645,3374,651,591,0646,569,664,5759,301,455,77111,108,065,91412,580,279,23513,227,512,20413,945,496,95216,094,149,97517,989,536,24018,998,310,34213,576,114,5317,951,956,6088,593,199,7798,674,014,165
Net income
1.07b
171,278,731193,514,199205,500,128177,743,468255,887,518316,706,340450,301,670610,811,248769,203,2961,100,261,4781,368,270,7691,478,548,9861,176,424,9391,376,542,1911,545,167,9821,001,424,9971,125,891,1672,358,864,97001,071,072,344
CFO
2.58b
+12.71%
203,266,603214,897,007140,562,860221,554,434260,207,628400,387,357395,052,912135,135,367413,310,499346,172,870616,763,924340,002,0931,153,728,62001,493,789,7221,680,149,9781,791,167,0182,801,160,3722,285,134,8122,575,634,584
Dividend
Oct 10, 20240.26 CNY/sh
Earnings
May 08, 2025

Profile

Tasly Pharmaceutical Group Co., Ltd. engages in biological medicine, health, and medical service businesses in China. It offers herbal and chemical medicines, health products, pharmaceutical substances and APIs, herbal extracts, concentrated herbal granules, and tea series products. The company also provides cosmetic series products, including moisture lotions, moisture creams, eye creams, and face washing foams; daily hygiene products, such as sanitary and carefree pads, honey-propolis soaps, and pollen soaps; and medical equipment, which include massage tappers, massage cushions, and circulation machines. It also exports its products to the United States, Russia, and countries in Europe, Africa, and rest of Asia. Tasly Pharmaceutical Group Co., Ltd. was founded in 1994 and is based in Tianjin, China.
URL
https://www.taslypharma.com/
IPO date
Aug 23, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,674,014
0.94%
8,593,200
8.06%
7,951,957
-41.43%
Cost of revenue
5,983,665
6,916,635
6,328,387
Unusual Expense (Income)
NOPBT
2,690,350
1,676,565
1,623,569
NOPBT Margin
31.02%
19.51%
20.42%
Operating Taxes
204,457
180,303
315,925
Tax Rate
7.60%
10.75%
19.46%
NOPAT
2,485,893
1,496,262
1,307,645
Net income
1,071,072
 
2,358,865
109.51%
Dividends
(493,004)
(493,004)
(495,716)
Dividend yield
1.94%
3.06%
2.08%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,277,026
714,031
577,546
Long-term debt
1,576,014
1,526,332
1,197,667
Deferred revenue
177,791
214,570
Other long-term liabilities
160,118
1
1
Net debt
(3,951,898)
(2,380,611)
(2,016,142)
Cash flow
Cash from operating activities
2,575,635
2,285,135
2,801,160
CAPEX
(668,819)
Cash from investing activities
(2,108,558)
Cash from financing activities
(1,196,349)
FCF
3,281,263
2,293,150
2,981,189
Balance
Cash
4,751,309
4,234,810
3,791,355
Long term investments
2,053,629
386,164
Excess cash
6,371,237
4,191,314
3,393,757
Stockholders' equity
11,911,761
11,507,889
12,120,660
Invested Capital
9,250,407
10,630,987
11,627,577
ROIC
25.01%
13.44%
10.85%
ROCE
17.22%
11.29%
10.78%
EV
Common stock shares outstanding
1,493,950
1,495,260
1,501,577
Price
17.02
58.18%
10.76
-32.11%
15.85
7.17%
Market cap
25,427,029
58.04%
16,089,002
-32.40%
23,799,991
7.07%
EV
21,796,720
13,973,244
22,116,408
EBITDA
3,195,261
2,193,427
2,111,336
EV/EBITDA
6.82
6.37
10.48
Interest
87,259
64,411
77,391
Interest/NOPBT
3.24%
3.84%
4.77%